NAMPT and early-onset autosomal dominant Alzheimer disease: It has been demonstrated that P7C3 and its analogs have neuroprotective efficacy in a broad range of preclinical rodent and nonhuman primate models relying on the activation of NAMPT.635–638 Therefore, the neuroprotective activity of P7C3 offers a new pharmacotherapy for age-associated ALS, Alzheimer’s disease and Parkinson’s disease.635,637,638 SBI-797812 activates NAMPT via stabilizing the NAMPT phosphorylation at His247, enhancing the efficiency of NMN generation, providing another option to raise NAD+.